Aigner K R, Gailhofer S, Kopp S
Asklepios Paulinen Klinik, Abteilung fur Chirurgische Onkologie, Wiesbaden, Germany.
Hepatogastroenterology. 1998 Jul-Aug;45(22):1125-9.
BACKGROUND/AIMS: In an attempt to improve treatment protocols for advanced pancreatic cancer, the value of regional chemotherapy compared with systemic chemotherapy was investigated in this randomized study.
Fourteen patients with advanced non-resectable pancreatic adenocarcinoma were randomized receiving either systemic chemotherapy with mitomycin, mitoxanthrone and cisplatin (5pts.) or celiac axis infusion regional chemotherapy with SpherexR microembolization. In the systemic group one patient was stage III, four patients were stage IV, in the intraarterial group two patients were specified stage III and seven were stage IV.
In the systemic group one stable disease and four progressive diseases were noted, in the regional group two stable diseases and seven partial responses were noted. Median survival was 11 weeks in the systemically treated patients versus 33 weeks in the patients treated with intraarterial infusion (p=0.001). One patient became resectable (R0).
Performance status improved during regional chemotherapy whilst it steadily decreased in the patients treated systemically. The study was terminated at that point.
背景/目的：为改进晚期胰腺癌的治疗方案，本随机研究对区域化疗与全身化疗的价值进行了调查。
14例晚期不可切除胰腺腺癌患者被随机分组，分别接受丝裂霉素、米托蒽醌和顺铂的全身化疗（5例）或腹腔动脉灌注联合SpherexR微栓塞区域化疗。全身化疗组1例为Ⅲ期，4例为Ⅳ期；动脉内化疗组2例为Ⅲ期，7例为Ⅳ期。
全身化疗组观察到1例病情稳定和4例病情进展，区域化疗组观察到2例病情稳定和7例部分缓解。全身治疗患者的中位生存期为11周，动脉内灌注治疗患者为33周（p = 0.001）。1例患者变为可切除（R0）。
区域化疗期间患者的体能状态有所改善，而全身治疗患者的体能状态则持续下降。研究因此提前终止。
